Kinvard Bio is creating a new class of antibiotics to treat drug-resistant infections and diseases.

Sponsored research agreement between Harvard and Roche resulted in the Kahne Lab’s discovery of the mechanism of action for Roche’s compound, paving the way for the development of new antibiotics.

Harvard researchers have created an antibiotic that can overcome many drug-resistant infections.

Researchers at the Andrew G Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology are engineering synthetic antibiotics that directly target bacteria which cause lower respiratory tract and skin and soft tissue infections.